<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1149">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03999879</url>
  </required_header>
  <id_info>
    <org_study_id>18-01919</org_study_id>
    <nct_id>NCT03999879</nct_id>
  </id_info>
  <brief_title>PhosphoRus, Proton Imaging and Amyloid BuRdEn (PREPARE) ON AMYLOID BURDEN AND COGNITION</brief_title>
  <acronym>PREPARE</acronym>
  <official_title>Neuroenergetic Adaptations in Alzheimer's Disease: Implications on Amyloid Burden and Cognition.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Normal cells primarily produce energy with the help of the &quot;mitochondria&quot;. These &quot;small&#xD;
      organs&quot; are also called the &quot;powerhouses of the cell&quot; turn the sugars, fats and proteins that&#xD;
      is eaten into forms of chemical energy that the body can use to carry on living. This process&#xD;
      is called oxidative phosphorylation. In addition to the help from the mitochondria and&#xD;
      oxidative phosphorylation, most cells can produce energy by lactic acid fermentation. This&#xD;
      process is less energy efficient but faster and used by the brain, muscle or other organs&#xD;
      under specific circumstances and energy demands, even in the presence of abundant oxygen. It&#xD;
      is also called aerobic glycolysis. Aerobic glycolysis and oxidative phosphorylation are the&#xD;
      two major mechanisms involved in brain energetics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The consequences of Alzheimer's disease (AD) (deposition of amyloid plaques and&#xD;
      neurofibrillary tangles) are known. The cause of these deposition of proteins is not. Some&#xD;
      scientist argue that an increase in oxidative phosphorylation activity and a lack of ability&#xD;
      to shift to aerobic glycolysis are the underlying source of these changes. The purpose of&#xD;
      this study is to test whether there is a correlation between neuroenergetic levels of aerobic&#xD;
      glycolysis/oxidative phosphorylation and risk for Alzheimer's disease. The study will examine&#xD;
      these neuroenergetic adaptations in a group of 15 elderly participants (age range: 70-85 y/o)&#xD;
      with amnestic mild cognitive impairment (aMCI) and 30 cognitively normal controls (NL).&#xD;
      Multimodal (MR/PET) and multinuclear (31P/1H) neuroimaging will allow us to gain access to a&#xD;
      uniquely comprehensive and highly consistent view of neuroenergetic adaptations in both the&#xD;
      clinical and preclinical stages of Alzheimer's disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>(PCr)-to-ATP ratio levels</measure>
    <time_frame>1 Month</time_frame>
    <description>These 31P-MRSI data will differentiate PiB+ aMCI individuals from PiB+ NL individuals.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Cognitively Normal</arm_group_label>
    <description>having 30 participants with normal cognition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amnesic MCI</arm_group_label>
    <description>aMCI Group having 15 participants with a CDR of 0.5-1 and a Mini-Mental State Examination (MMSE) of 20-25.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Measure of OxPhos upregulation</intervention_name>
    <description>OxPhos upregulation [i.e., lower phosphocreatine (PCr)-to-ATP ratio levels] in the PET AG mask. PIB+ NL subjects will show OxPhos downregulation (i.e. increased PCr/ATP ratio that indicate the presence of metabolically inert PCr that cannot be used as ATP) when compared to PIB- NL subjects in the PETAG mask</description>
    <arm_group_label>Amnesic MCI</arm_group_label>
    <arm_group_label>Cognitively Normal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>lactate (measured with 1H-MRSI)</intervention_name>
    <description>PIB+ NL subjects will show increased levels of lactate (measured with 1H-MRSI) when compared to PIB- NL subjects in the PETAG mask.</description>
    <arm_group_label>Amnesic MCI</arm_group_label>
    <arm_group_label>Cognitively Normal</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults (male and female) aged &gt;70 years in overall excellent health with normal cognition&#xD;
        (CDR=0), and at least high school graduate level education.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  NL Group: Adults (male and female) aged &gt;70 years in overall excellent health with&#xD;
             normal cognition (CDR=0), and at least high school graduate level education.&#xD;
&#xD;
          -  aMCI Group: Adults (male and female) aged &gt;70 years, Clinical Dementia Rating (CDR)=&#xD;
             0.5 - 1 and Mini-Mental State Examination (MMSE): 20-25&#xD;
&#xD;
          -  English as first language or demonstrated proficiency in English for non-native&#xD;
             speakers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any tumor, stroke, or trauma that would result in abnormal radiological findings&#xD;
             History of bipolar disorder, schizophrenia, intellectual disability or substance abuse&#xD;
             MRI scanner contraindications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Langone Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katherine Medina</last_name>
    <phone>212-263-5053</phone>
    <email>katherine.medina@nyulangone.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Medina</last_name>
      <phone>212-263-0228</phone>
      <email>katherine.medina@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Ryan Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2022</verification_date>
  <study_first_submitted>June 25, 2019</study_first_submitted>
  <study_first_submitted_qc>June 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2019</study_first_posted>
  <last_update_submitted>August 3, 2022</last_update_submitted>
  <last_update_submitted_qc>August 3, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

